The latest price target for Immunocore Hldgs (NASDAQ:IMCR) was reported by Morgan Stanley on December 13, 2024. The analyst firm set a price target for $35.00 expecting IMCR to rise to within 12 months (a possible 23.57% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Immunocore Hldgs (NASDAQ:IMCR) was provided by Morgan Stanley, and Immunocore Hldgs downgraded their equal-weight rating.

The last upgrade for Immunocore Holdings PLC happened on December 16, 2022 when Goldman Sachs raised their price target to N/A. Goldman Sachs previously had a neutral for Immunocore Holdings PLC.

The last downgrade for Immunocore Holdings PLC happened on December 13, 2024 when Morgan Stanley changed their price target from $74 to $35 for Immunocore Holdings PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunocore Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunocore Hldgs was filed on December 13, 2024 so you should expect the next rating to be made available sometime around December 13, 2025.

While ratings are subjective and will change, the latest Immunocore Hldgs (IMCR) rating was a downgraded with a price target of $74.00 to $35.00. The current price Immunocore Hldgs (IMCR) is trading at is $28.33, which is out of the analyst’s predicted range.